Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
8.97M
-
Shares change
-
+6.04M
-
Total reported value, excl. options
-
$17.9M
-
Value change
-
+$12M
-
Put/Call ratio
-
0.19
-
Number of buys
-
54
-
Number of sells
-
-13
-
Price
-
$2.00
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q2 2023
80 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q2 2023.
Protalix BioTherapeutics, Inc. - COM (PLX) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.97M shares
.
Largest 10 shareholders include BlackRock Inc. (2.64M shares), STATE STREET CORP (731K shares), RENAISSANCE TECHNOLOGIES LLC (659K shares), MARSHALL WACE, LLP (562K shares), GEODE CAPITAL MANAGEMENT, LLC (552K shares), NORTHERN TRUST CORP (363K shares), NATIONAL BANK OF CANADA /FI/ (304K shares), JANE STREET GROUP, LLC (276K shares), Nuveen Asset Management, LLC (262K shares), and VANGUARD GROUP INC (230K shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.